

Correlates of serum IGF-1 in young children with moderate acute malnutrition: a cross-sectional study in Burkina Faso

Thora W. Kjaer⁵; Benedikte Grenov¹; Charles W. Yaméogo^{1,2}; Christian Fabiansen^{1,8}; Ann-Sophie Iuel-Brockdorff¹; Bernardette Cichon¹; Nick S. Nielsen¹; Suzanne Filteau³; André Briend^{1,7}; Jonathan C. K. Wells⁴; Kim F. Michaelsen¹; Henrik Friis¹; Daniel Faurholt-Jepsen¹; Vibeke B. Christensen^{5,6}

¹ Department of Nutrition, Exercise and Sports, University of Copenhagen, Denmark

² Département Biomédical et Santé Publique, Institut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso

³ Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, UK

⁴ UCL Great Ormond Street Institute of Child Health, University College London, UK

⁵ Department of Pediatrics and Adolescent Health, Rigshospitalet, Denmark

⁶ Médecins Sans Frontières – Denmark, Copenhagen, Denmark

⁷ Department for International Health, University of Tampere, School of Medicine, Tampere, Finland

⁸ The Pediatric Department, Holbæk Sygehus, DK-4300 Holbæk, Denmark

Corresponding author:

Thora Wesenberg Kjaer, Blegdamsvej 9, DK-2100 Copenhagen, Denmark, phone +4535452360, Thora.wesenberg.kjaer@regionh.dk

Funding:

The study was funded by Danish International Development Agency (09-097 LIFE) Médecins Sans Frontières (Denmark, Norway); Arvid Nilsson's Foundation; The World Food Program, which was part of a donation to the World Food Program from the American people through the support of the US Agency for International Development's Office of Food for Peace; the Alliance for International Medical Action; and the European Union's humanitarian aid funds, in partnership with Action Contre la Faim. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Short running title:

Correlates of IGF-1 in children with MAM

Abbreviations:

AGP: α 1-acid glycoprotein

CRP: C-reactive protein

DXA: Dual-energy X-ray absorptiometry

FFM: Fat free mass

FFMI: Fat free mass index

FM: Fat mass

FMI: Fat mass index

GH: Growth hormone

HRP2: Histidine rich protein 2

IGF-1: Insulin-like growth factor 1

IMCI: Integrated Management of Childhood Illnesses

LAZ: Length-for-age Z-score

MAM: Moderate acute malnutrition

MUAC: Mid-upper arm circumference

NEXS: Department of Nutrition, Exercise and Sports

RDT: Rapid diagnostic test

RPM: Revolutions per minute

SAM: Severe acute malnutrition

TBW: Total body water

VIF: Variance inflation factor

WAZ: Weight-for-age Z-score

WLZ: Weight-for-length Z-score

Clinical trial registration number:

ISRCTN42569496, <https://www.isrctn.com/>

Word count: 3390

Data described in the manuscript, code book, and analytic code will not be made available because the Danish Act on Data Protection does not allow for personal data to be made available to others without prior individual approval from the Danish Data Protection Agency.

1 **Abstract**

2 Background: Serum IGF-1 (sIGF-1) is an important growth factor in childhood. However,
3 studies on sIGF-1 among children from low-income countries are few and the role of body
4 composition are unknown.

5 Objective: To assess the associations of anthropometry, body composition, inflammation and
6 breastfeeding with sIGF-1 among children with moderate acute malnutrition (MAM).

7 Design: A cross-sectional study based on admission data from 6-23 months old children with
8 MAM participating in a nutrition intervention trial (Treatfood, ISRCTN42569496) in Burkina
9 Faso. Linear regression analysis was used to identify correlates of sIGF-1.

10 Results: Among 1546 children, the median [interquartile range] sIGF-1 was 12 [8.2-18.3]
11 ng/mL. Serum IGF-1 was highest at 6 months with a nadir around 10-11 months, and higher
12 in girls than boys. Length-for-age Z-score (LAZ), weight-for-length Z-score (WLZ) and mid-
13 upper arm circumference were positively associated with sIGF-1 ($p \leq 0.001$). Fat-free mass
14 (FFM) was also positively associated, as sIGF-1 increased 1.5 (95% CI 0.5, 2.5) ng/ml for
15 each 1 kg increase in FFM. However, the association disappeared after adjustment for height.
16 Elevated serum C-reactive protein (CRP) and α 1-acid glycoprotein (AGP) were negatively
17 associated with sIGF-1 ($p \leq 0.001$), as was fever ($p < 0.001$), but not a positive malaria test per
18 se ($p = 0.15$). Children never breastfed had lower sIGF-1 (-5.1, 95% CI -9.8, -0.3).

19 Conclusion: LAZ and WLZ were positively and inflammation negatively associated with
20 sIGF-1. As all children were moderately malnourished and many had inflammation, this
21 probably explains the very low median sIGF-1. The association of FFM with sIGF-1 was
22 fully explained by height. There was a marked age pattern, with a nadir in late infancy,

23 confirming findings from smaller studies from well-nourished populations. There is a need
24 for prospective studies to disentangle the role of sIGF-1 in growth and health.

25 **Key words:** moderate acute malnutrition, insulin-like growth factor (IGF-1), low-income
26 country, body composition, inflammation

27

28 **Introduction**

29 Moderate acute malnutrition (MAM) affects approximately 33 million children under five
30 years of age worldwide and is associated with increased morbidity and mortality from
31 infectious diseases [1]. Serum IGF-1 (sIGF-1) is an important growth factor both prenatally
32 and during childhood [2, 3]. Positive associations between sIGF-1 concentrations and height
33 and weight have been reported in children from high-income countries [4-6] and
34 malnourished children seem to have lower sIGF-1 than age-matched controls [7]. Studies in
35 well-nourished children have also found positive associations of fat-free mass (FFM), and to
36 a lesser extent fat mass (FM), with sIGF-1 [5, 6]. Similarly, changes in sIGF-1 were shown to
37 be associated with changes in FFM, but not FM in 6-9 year-old Ghanaian children with
38 stunting and wasting prevalences of 12% and 10%, respectively [8]. In general, sIGF-1
39 concentrations vary considerably in children, depending on their age, sex, ethnicity, socio-
40 economic status and nutrition [9-12].

41 Inflammation is another important factor influencing sIGF-1 concentrations. Children with
42 chronic inflammatory conditions often have growth failure and the underlying pathology
43 seems to be multifactorial. Both an effect of the inflammatory response on the growth
44 hormone (GH)-IGF-1 axis and an effect of suboptimal nutrition have been suggested to play
45 important roles [13]. In low-income settings, environmental enteric dysfunction,
46 characterized by malabsorption and intestinal inflammation and permeability, is associated
47 with stunting [14]. A Brazilian case-control sub-study found relations between systemic
48 inflammation, the GH-IGF-1 axis and growth in 6-24 month old children with varying
49 degrees of malnutrition. Children with recent infections had lower sIGF-1, and serum C-
50 reactive protein (CRP) was negatively associated with sIGF-1 [15]. A birth cohort study of
51 Zimbabwean infants showed that acute infection decreased sIGF-1 both through acute phase

52 response and by direct downregulation of IGF-1 [16]. This suggests a complex relationship
53 between malnutrition, inflammation and IGF-1.

54

55 The aim of this study was to investigate sex and age patterns of sIGF-1 concentrations from
56 1546 young children with MAM from Burkina Faso and to assess the association of

57 anthropometry, body composition, inflammation and breastfeeding with sIGF-1 in this large

58 population.

59 **Subjects and Methods**

60 *Study design, area and population*

61 This cross-sectional study was based on admission data from a cohort of children with MAM
62 enrolled in a nutrition intervention trial (Treatfood, ISRCTN42569496). The study was
63 carried out in the Passoré Province, Northern Region, Burkina Faso. The region is located in
64 the Sudano-Sahaelian zone, with an average yearly rainfall of 600-700 mm. The catchment
65 area covered 143 villages and a total population of approximately 258,000.

66

67 Children aged 6-23 months with MAM, resident in the catchment area, and whose
68 parents/guardians consented for their child to participate, were eligible. Children were
69 excluded if they had been treated for severe acute malnutrition (SAM) or hospitalized within
70 the past two months, had participated in a nutritional program, required hospitalization, or
71 had severe disability. Screening was carried out by community health workers using mid-
72 upper arm circumference (MUAC) tapes or by designated screening teams assessing both
73 MUAC and weight-for-length z-score (WLZ). In addition, children could be referred from a
74 health center or could present at site on caretaker's initiative. Recruitment took place from
75 September 2013 until August 2014. Children were classified with MAM if $WLZ \geq -3$ and < -2
76 and/or MUAC was ≥ 115 and < 125 mm [17]. WLZ was determined using WHO field charts
77 [18] and later recalculated. Final analyses of WLZ was recalculated using the package
78 `zscore06` in STATA 12 (StataCorp, US). Children could be enrolled in one of three groups
79 fulfilling either MAM criteria for both WLZ (< -2 and ≥ -3) and MUAC (< 125 mm and ≥ 115
80 mm), WLZ only or MUAC only. WLZ was divided into 2 groups, $WLZ \geq -2$ and < -2 . MUAC
81 was divided into 3 groups, MUAC ≥ 125 mm, ≥ 120 mm and < 125 mm, and < 120 mm.

82

83 *Data collection*

84 Weight was measured to the nearest 100 g using an electronic scale (Seca model 881
85 1021659), length was measured with a wooden length board to the nearest 1 mm and MUAC
86 was measured at the midpoint between the olecranon and the acromion process to the nearest
87 1 mm using a standard measuring tape. All were measured in duplicate by trained study staff
88 and the average was used. Study nurses were trained and supervised by a study physician and
89 collected 2.5 mL of venous blood from the arm of each participant. One drop of blood was
90 used for diagnosis of malaria on site using a rapid diagnostic test (RDT) (Bioline Malaria Ag
91 P.f. Standard diagnostics inc.) that detects histidine rich protein 2 (HRP2) synthesized by the
92 *Plasmodium falciparum* malaria parasite. Since HRP2, the protein detected by the RDT, can
93 persist in blood for over a month after treatment of malaria, a positive RDT in the absence of
94 clinical findings may be due to either a treated infection or asymptomatic malaria. We
95 therefore present prevalence of children with a positive RDT accompanied by fever in
96 addition to prevalence of positive RDT independent of fever. The remaining blood from each
97 sample was collected in serum vacutainers (Becton Dickinson, reference #368492) and
98 transported to the trial laboratory in a cold box at 2-8°C. Serum was isolated following
99 centrifugation at 3000 RPM for 5 minutes (EBA 20S Hettich), stored at -20°C, and sent to
100 VitMin Lab in Willstaedt, Germany for analysis of CRP and α 1-acid glycoprotein (AGP).
101 Serum CRP and AGP were determined using a simple sandwich enzyme-linked
102 immunosorbent assay [19]. The intra- and interassay co-efficients of variation for serum CRP
103 and AGP were <10%. Serum IGF-1 was analyzed on an Immulite 2000 Analyzer, (Siemens
104 Healthcare, GmbH) at NEXS in Copenhagen, Denmark. Values below 25 ng/mL were not
105 displayed automatically, but were calculated using algorithms according to correspondence
106 with the manufacturer. The intra-assay co-efficient of variation was 20% when sIGF-1 was
107 10 ng/mL and 6% when sIGF-1 was 25 ng/mL. All samples were measured in duplicate and
108 the average was used.

109

110 Study nurses collected data on illness using a patient history based on 14-day maternal recall
111 and carried out a physical examination. A child was considered ill if the caretaker reported
112 that their child in the previous two weeks had any of the following symptoms: fever, cough,
113 diarrhea, vomiting, breathing problems, reduced appetite, rash, pain or swelling. A child was
114 considered ill if the physical examination found skin problem (rash, ulcer, infection or other),
115 respiratory tract infections, ear infection, diarrhea, oral thrush, mouth ulcer, fever or malaria.
116 Binary morbidity variables were generated based on both maternal recall and physical
117 examination. Diarrhea was defined as three or more loose or watery stools per day based on
118 maternal information [20]. Respiratory tract infections were diagnosed using an adapted
119 version of the Integrated Management of Childhood Illnesses (IMCI) guidelines. Fever was
120 defined as an axillary temperature $\geq 37.5^{\circ}\text{C}$ at physical examination [20]. Data on
121 breastfeeding was collected based on maternal or caretaker information on present or past
122 breastfeeding.

123

124 Fat-free mass (FFM) was assessed using the deuterium dilution technique as previously
125 described [21, 22]. In short, pre-dose saliva samples were collected before an oral
126 administration of 5 g D₂O diluted in 5 g of bottled water, weighed with 0.01 g precision.
127 After a 3 hours equilibration period, post-dose saliva samples were collected. Duplicate
128 measurements were performed on pre- and post-dose saliva samples and on a diluted sample
129 of each child's dose. Fourier-transform infrared spectrometry was used to calculate D₂O
130 abundance. From that, D₂O dilution space was calculated and further converted into total
131 body water (TBW). Hydration coefficients based on age and sex were used to calculate FFM
132 as TBW/hydration. Fat mass (FM) was defined as weight minus FFM. Typographical errors
133 and implausible TBW values were cleaned from the data, based on the association of TBW

134 with length and cutoffs for FM of <-0.1 (to account for the normal technical variability in
135 deuterium dilution studies) and >2.4 kg. To obtain length-adjusted indices, FFMI and FMI
136 were calculated as FFM and FM divided by length in meters squared [23].

137

138 *Outcomes and sample size*

139 IGF-1 was a secondary outcome in the Treatfood study together with FFM, FM, FMI, weight,
140 length, knee-heel length, MUAC, triceps skinfold, and nutritional recovery. The primary
141 outcome FFMI has already been published [21]. The aims to identify sex and age patterns and
142 correlates of serum IGF-1 were exploratory. The sample size of the current study was fixed as
143 it involves baseline data from the Treatfood study.

144

145 *Data handling and statistical analysis*

146 Data was double entered into EPIDATA 3.1 software (Epidata Association, Odense,
147 Denmark). All statistical analyses were carried out using STATA version 12 (StataCorp,
148 Collage Station TX, USA). Children with missing values were excluded from the analysis.
149 Baseline characteristics, reported illness, body composition, and serum concentrations of
150 IGF-1, AGP and CRP were summarized as percentage (n), mean (standard deviation, SD) for
151 normally distributed variables or median (interquartile range, IQR) for non-normally
152 distributed variables based on visual inspection of histograms and probability plots. Linear
153 regression models were used to assess the association of admission criteria, WLZ, length-for-
154 age z-score (LAZ), weight-for-age z-score (WAZ), MUAC, body composition, CRP, AGP,
155 breastfeeding, fever, positive malaria test, and a positive or negative malaria test both with
156 and without fever with sIGF-1. CRP was divided into five groups (≤ 2 mg/L, >2 and ≤ 5 mg/L,
157 >5 and ≤ 10 mg/L, >10 and ≤ 50 mg/L and >50 mg/L). AGP was divided into three groups
158 (<0.8 g/L, $0.8-1.2$ g/L and >1.2 g/L). All linear regressions were reported unadjusted and

159 adjusted for age and sex and checked for collinearity using variance inflation factors (VIF).
160 Collinearity was not present in any of the models as all VIFs ≤ 3 . Additionally, the linear
161 regression for sIGF-1 as a function of WLZ was adjusted for MUAC, sIGF-1 as a function of
162 MUAC was adjusted for WLZ, and sIGF-1 as a function of admission criteria was adjusted
163 for AGP. Model assumptions were checked using residual and normal probability plots
164 respectively. An alpha of 0.05 was used in test of significance. Fractional polynomials with
165 95% confidence intervals (95%CI) were used to present sIGF-1 depending on age for boys
166 and girls separately.

167 **Results**

168 Of 1609 children enrolled, sIGF-1 data were available on 96% (n=1546) (**Figure 1**). Of these,
169 21% (n=324) were enrolled based on WLZ, 29% (n=451) based on MUAC, and 50% (n=771)
170 based on both WLZ and MUAC. Mean (\pm SD) age of the children was 12.4 (\pm 4.9) months,
171 45% (n=699) were boys, WLZ was -2.2 (\pm 0.5), MUAC was 123 (\pm 4.0) mm., 79% (1208) had
172 been ill in the last two weeks and 94% (1453) were still breastfed (**Table 1**). The median
173 [interquartile range] sIGF-1 at enrollment was 12 [8.2-18.3] ng/mL (Table 1). Serum IGF-1
174 was highest in children aged 6 months with nadir just before 10 months for girls and around
175 11 months for boys and it was positively associated with age from nadir to 24 months
176 (**Figure 2**). As seen from the confidence intervals, girls had higher mean serum IGF-1 than
177 boys throughout the age range.

178

179 *Anthropometry, body composition and serum IGF-1*

180 After adjustment for age and sex, those admitted based on MUAC only had 2.2 (95%CI
181 0.9,3.5) ng/mL higher sIGF-1 and those admitted based on WLZ only had 1.6 (95%CI
182 0.2,3.1) ng/mL higher sIGF-1 than those admitted based on both WLZ and MUAC (**Table 2**).
183 Further adjustment for elevated serum AGP did not change these estimates (data not shown).
184 LAZ was positively associated with sIGF-1. The regression coefficient of 1.0 (95%CI
185 0.5,1.5) reflects that sIGF-1 is 1.0 ng/mL higher for each 1 unit increase in LAZ. If used as
186 categorical variable with LAZ \geq -2 as reference, then LAZ <-3 (severe stunting) was
187 associated with a 2.8 (95%CI 0.9,4.7) ng/mL lower sIGF-1, whereas those with LAZ between
188 -3 and -2 (moderate stunting) did not differ from the reference. WAZ and WLZ were also
189 positively associated with sIGF (2.6 95%CI 1.7,3.4 and 2.2, 95%CI 1.0,3.3) Further
190 adjustment of WLZ for MUAC or height did not considerably change the estimate (data not
191 shown). Similarly, MUAC was positively associated with sIGF-1 (0.3, 95%CI 0.1, 0.4), and

192 further adjustment for WLZ or height did not considerably change the estimate (data not
193 shown). FFM was positively associated with sIGF-1 (1.5, 95%CI 0.5, 2.5), but the height-
194 adjusted index FFMI was not. Likewise, FM tended to be associated with sIGF-1 ($p = 0.067$),
195 but FMI was not (**Table 2**). FFM and FM were not associated with sIGF-1 after adjustment
196 for length (data not shown).

197

198 *Breastfeeding, paraclinical and clinical markers of inflammation and serum IGF-1*

199 After adjustment for age and sex, elevated serum CRP or AGP were associated with lower
200 sIGF-1 (**Table 3**). In addition, being ill in the last 2 weeks (-2.3 95%CI -3.7,-1.0), having
201 diarrhea (-2.6 95%CI -4.0,-1.3), cough (-1.5 95%CI -2.8,-0.3) or fever (-2.8 95%CI -4.3,-1.4)
202 were associated with lower sIGF-1. Similarly, fever, with (-3.6, 95%CI -5.7,-1.5) or without
203 (-2.9, 95%CI -4.9,-0.9) a positive malaria test, but not a positive malaria test without fever
204 ($p=0.15$), was associated with lower sIGF-1. Never (-5.1 95%CI -9.8,-0.3) and previous (-2.3
205 95%CI -5.1,0.4) breastfeeding were associated with lower sIGF-1, although the latter was
206 only a tendency ($p = 0.095$). Further adjustment for MUAC and WLZ did not change the
207 estimates (data not shown).

208 **Discussion**

209 The very low levels of sIGF-1 in our study are probably explained by all children having
210 MAM, a high proportion with inflammation, and the young age. Previous studies in younger
211 age groups have mainly been among children from high-income countries with little stunting
212 and wasting.

213

214 The median sIGF-1 was 12 ng/mL, which is lower than previously found in healthy children
215 [5, 9, 24, 25]. Another study from Burkina Faso in apparently healthy 6-23 months children
216 found lower sIGF-1 concentrations compared to children from high-income countries [11].
217 However, those children had a mean sIGF-1 between 24.8 ng/mL and 28.9 ng/mL,
218 approximately double the concentration compared to our study for both sexes. A small case-
219 control study in malnourished children from Chile aged 5-26 months with mean WLZ of -2.7
220 found a mean sIGF-1 around 4 ng/mL [7]. This study supports our finding of lower sIGF-1 in
221 malnourished children. The difference between sIGF-1 concentrations in the study from
222 Burkina Faso and the other studies in healthy children may be due to differences in dietary
223 intake, and perhaps differences in ethnicity [26] or analytical methods.

224

225 *Age and sex*

226 Serum IGF-1 was highest in children aged 6 months, had a nadir at around 10-11 months, and
227 was positively associated with age from nadir until 24 months. Studies on well-nourished
228 children have shown a similar pattern although it was less clear due to fewer children and
229 sampling points [9, 24]. However, when combining results from different studies covering
230 the age range up to 24 months, a similar age pattern was shown, which supports the clear age
231 pattern shown in the present study [24]. A review showed that sIGF-1 concentrations

232 increased until 3 months, decreased from 3-8 months with a nadir at 8 months and then
233 slowly increased until puberty [24].

234 Our study also found higher sIGF-1 in girls than in boys. This is in line with other large
235 studies [27, 28]. Studies in children at 3 months of age found no difference in sIGF-1
236 between girls and boys [29, 30], but sIGF-1 in children at 12 months was higher in girls than
237 boys [30]. The lack of difference in sIGF-1 concentrations between girls and boys at 3
238 months suggests that sIGF-1 are higher in girls than boys at most but not at all ages.

239

240 *Inflammation and infections*

241 The negative associations of inflammatory markers CRP and AGP with sIGF-1 supports the
242 findings of earlier studies [15, 16]. A longitudinal study in both stunted and non-stunted
243 Zimbabwean children between 0-18 months found that acute illness was associated with a
244 suppression of the GH axis with lower sIGF-1 mediated via both an indirect pathway through
245 the acute phase response and a direct pathway on sIGF-1 [16]. Not only acute infection, but
246 also chronic inflammatory diseases in children are associated with lower sIGF-1 [13, 31].
247 Children from low-income settings with poor sanitation may suffer from frequent infections
248 and environmental enteric dysfunction, a syndrome associated with intestinal inflammation
249 [14]. Our study found that children with fever had lower sIGF-1 compared to children
250 without fever both with or without a positive malaria test. This indicates that the
251 inflammatory response present during fever suppresses sIGF-1 [15]. In addition, children
252 with cough or diarrhea had lower sIGF-1. Similarly, Zimbabwean children with diarrhea and
253 cough [16] and Brazilian children with diarrhea, but not those with cough [15], had lower
254 sIGF-1.

255 A lower sIGF-1 in children with illness was further supported by the paraclinical findings.

256 Children with a positive malaria test and fever had an even lower sIGF-1 compared to

257 children with only fever, diarrhea or cough, suggesting that malaria has a worse or more
258 prolonged inflammatory response than other infections. Previous infection with malaria,
259 without persisting fever, was not associated with lower sIGF-1, suggesting a reversibility of
260 the depressed sIGF-1 when the inflammatory response is removed. This is supported in the
261 Zimbabwean study, where fever the previous day was associated with lower sIGF-1, but
262 fever two weeks before was not [16].

263

264 *Anthropometry and body composition*

265 Children with both low MUAC and low WLZ had lower sIGF-1 compared to children with
266 only low MUAC or low WLZ. This supports previous findings that malnutrition negatively
267 influences sIGF-1 [7]. This study found that WLZ, MUAC and HAZ were positively
268 associated with sIGF-1. Previous studies in both high- and low-income countries have also
269 found a positive association between anthropometric measurements and sIGF-1 [5, 11, 32,
270 33]. Our study found an association between FFM and sIGF-1 concurrent with other studies
271 [5, 6, 8, 33, 34]. The association of FM with sIGF-1 in our study only tended towards
272 significance. A Danish cohort of healthy children aged 9-36 months found that FM was
273 positively associated with sIGF-1, but not as strongly as FFM [5]. Most other studies found
274 similar results using both multiple skinfold measures [6, 30] and fat mass by DXA [33, 34].
275 Consistent with the Danish and Ghanaian studies, our study found no association between
276 FFMI, FMI and sIGF-1, suggesting that sIGF-1 is primarily affecting linear growth in
277 children [5, 8].

278

279 *Breastfeeding*

280 Our study found that children still breastfed had higher sIGF-1 compared to children that
281 were never breastfed. This differs from previous studies in well-nourished children where

282 breastfed children had lower sIGF-1 [4, 29, 30]. This is most likely because children in high-
283 income countries receive infant formula as a replacement for breastmilk. Infant formula has a
284 higher concentration of protein compared to breast milk, which leads to increased levels of
285 sIGF-1 [24, 29, 35], and even low-protein formula results in higher sIGF-1 in children than
286 breastmilk [35]. The children in our study did not receive infant formula, but rather family-
287 prepared foods with a low content of animal protein.

288

289 *Limitations and strength*

290 There were some limitations in our study. Firstly, the analysis kit to measure sIGF-1 was not
291 validated to measure the low concentrations observed in this study. The intra-assay
292 coefficient of variation was 20% when sIGF-1 was 10 ng/mL and 6% when sIGF-1 was 25
293 ng/mL or above, indicating that the analysis was less precise at low values. However, more
294 than 1500 tests measured in duplicate should compensate for the larger variation. Secondly,
295 the never-breastfed group was small and may have been insufficient to evaluate the effect of
296 breastfeeding with accuracy, nevertheless the data for previously breastfed children tended
297 towards a smaller but similar effect. In addition, there was an increased risk of Type 1 errors
298 due to the multiple statistical analyses. However, for the associations with very low
299 significance levels ($p < 0.001$), the risk of chance findings is considered low. Finally, due to
300 the cross sectional study design, there is a risk of residual confounding, which could not be
301 adjusted for. A strength of the study is the well-defined nutritional status of the children and
302 the large sample size, which provided greater power to identify correlates of sIGF-1.

303

304 *Conclusion*

305 LAZ and WLZ were strongly positively associated, and inflammation strongly negatively
306 associated, with sIGF-1. As all children had MAM and many had inflammation, this probably

307 explains the very low sIGF-1 values found. Nevertheless, the age-sex pattern confirms what
308 has been found in smaller studies in high-income settings. The associations of FFM and FM
309 with sIGF-1 were fully explained by height. There is a need for prospective and nutrition
310 intervention studies to further disentangle the role of sIGF-1 in growth and health in a
311 population with undernutrition.

312 **Acknowledgement**

313 We acknowledge the contributions of the study participants and their families, the research
314 staff, the Ministry of Health in Burkina Faso, the health and village authorities in Province du
315 Passoré, and the staff at the health centres.

316

317 **Statement of authors' contributions to manuscript:**

318 SF, AB, JW, VBC, HF, and KFM designed the Treatfood trial. AI, CWY, CF, and BC
319 conducted the research. TWK analyzed data and wrote the manuscript. BG, KM, HF, NSN,
320 DF and VBC contributed to data analysis. TWK had primary responsibility for final content.
321 All authors read and approved the final manuscript.

322

323 **Conflicts of interest:**

324 The authors declare no conflicts of interest.

325

References

- 326 1. UNICEF, W., and World Bank. *UNICEF/WHO/The World Bank Group joint child*
 327 *malnutrition estimates: levels and trends in child malnutrition: key findings of the*
 328 *2020 edition*. 2020; Available from: [https://www.who.int/publications/i/item/jme-](https://www.who.int/publications/i/item/jme-2020-edition)
 329 [2020-edition](https://www.who.int/publications/i/item/jme-2020-edition).
- 330 2. Benyi, E. and L. Savendahl, *The Physiology of Childhood Growth: Hormonal*
 331 *Regulation*. Horm Res Paediatr, 2017. **88**(1): p. 6-14.
- 332 3. Hill, D.J. and J. Hogg, *Growth factors and the regulation of pre- and postnatal growth*.
 333 Baillieres Clin Endocrinol Metab, 1989. **3**(3): p. 579-625.
- 334 4. Madsen, A.L., A. Larnkjær, C. Mølgaard, and K.F. Michaelsen, *IGF-I and IGFBP-3 in*
 335 *healthy 9 month old infants from the SKOT cohort: breastfeeding, diet, and later*
 336 *obesity*. Growth Horm IGF Res, 2011. **21**(4): p. 199-204.
- 337 5. Ejlerskov, K.T., A. Larnkjær, D. Pedersen, C. Ritz, C. Mølgaard, and K.F. Michaelsen,
 338 *IGF-I at 9 and 36 months of age — relations with body composition and diet at 3*
 339 *years — the SKOT cohort*. Growth Horm IGF Res, 2014. **24**(6): p. 239-44.
- 340 6. Ong, K., J. Kratzsch, W. Kiess, and D. Dunger, *Circulating IGF-I levels in childhood are*
 341 *related to both current body composition and early postnatal growth rate*. J Clin
 342 Endocrinol Metab, 2002. **87**(3): p. 1041-4.
- 343 7. Palacio, A.C., F. Perez-Bravo, J.L. Santos, L. Schlesinger, and F. Monckeberg, *Leptin*
 344 *levels and IgF-binding proteins in malnourished children: effect of weight gain*.
 345 Nutrition, 2002. **18**(1): p. 17-9.
- 346 8. Grenov, B., A. Larnkjær, R. Lee, A. Serena, C. Mølgaard, K.F. Michaelsen, and M.J.
 347 Manary, *Circulating Insulin-Like Growth Factor-1 Is Positively Associated with Growth*
 348 *and Cognition in 6- to 9-Year-Old Schoolchildren from Ghana*. J Nutr, 2020.
- 349 9. Yuksel, B., M.N. Ozbek, N.O. Mungan, F. Darendeliler, B. Budan, A. Bideci, E.
 350 Cetinkaya, M. Berberoglu, O. Evliyaoglu, E. Yesilkaya, et al., *Serum IGF-1 and IGFBP-3*
 351 *levels in healthy children between 0 and 6 years of age*. J Clin Res Pediatr Endocrinol,
 352 2011. **3**(2): p. 84-8.
- 353 10. Juul, A., P. Bang, N.T. Hertel, K. Main, P. Dalgaard, K. Jorgensen, J. Muller, K. Hall, and
 354 N.E. Skakkebaek, *Serum insulin-like growth factor-I in 1030 healthy children,*
 355 *adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and*
 356 *body mass index*. J Clin Endocrinol Metab, 1994. **78**(3): p. 744-52.
- 357 11. Kouanda, S., R. Tonglet, V. De Coninck, B. Doulougou, B. Sondo, J.M. Ketelslegers,
 358 and A. Robert, *Reference values of IGF-I in children from birth to 5 years of age, in*
 359 *Burkina Faso, using blood samples on filter paper*. Growth Horm IGF Res, 2008. **18**(4):
 360 p. 345-52.
- 361 12. Murray, P.G. and P.E. Clayton, *Endocrine control of growth*. Am J Med Genet C Semin
 362 Med Genet, 2013. **163c**(2): p. 76-85.
- 363 13. Wong, S.C., R. Dobie, M.A. Altowati, G.A. Werther, C. Farquharson, and S.F. Ahmed,
 364 *Growth and the Growth Hormone-Insulin Like Growth Factor 1 Axis in Children With*
 365 *Chronic Inflammation: Current Evidence, Gaps in Knowledge, and Future Directions*.
 366 Endocr Rev, 2016. **37**(1): p. 62-110.
- 367 14. Crane, R.J., K.D. Jones, and J.A. Berkley, *Environmental enteric dysfunction: an*
 368 *overview*. Food Nutr Bull, 2015. **36**(1 Suppl): p. S76-87.

- 369 15. DeBoer, M.D., R.J. Scharf, A.M. Leite, A. Ferrer, A. Havt, R. Pinkerton, A.A. Lima, and
370 R.L. Guerrant, *Systemic inflammation, growth factors, and linear growth in the*
371 *setting of infection and malnutrition*. Nutrition, 2017. **33**: p. 248-253.
- 372 16. Jones, A.D., S. Rukobo, B. Chasekwa, K. Mutasa, R. Ntozini, M.N. Mbuya, R.J.
373 Stoltzfus, J.H. Humphrey, and A.J. Prendergast, *Acute illness is associated with*
374 *suppression of the growth hormone axis in Zimbabwean infants*. Am J Trop Med Hyg,
375 2015. **92**(2): p. 463-70.
- 376 17. Organization), W.W.H., *Supplementary Foods for the Management of Moderate*
377 *Acute Malnutrition in Infants and Children 6–59 Months of Age*. 2012, WHO: Geneva.
- 378 18. Organization), W.W.H. *Weight-for-length/height: Charts* Available from:
379 [https://www.who.int/tools/child-growth-standards/standards/weight-for-length-](https://www.who.int/tools/child-growth-standards/standards/weight-for-length-height)
380 [height](https://www.who.int/tools/child-growth-standards/standards/weight-for-length-height).
- 381 19. Erhardt, J.G., J.E. Estes, C.M. Pfeiffer, H.K. Biesalski, and N.E. Craft, *Combined*
382 *measurement of ferritin, soluble transferrin receptor, retinol binding protein, and C-*
383 *reactive protein by an inexpensive, sensitive, and simple sandwich enzyme-linked*
384 *immunosorbent assay technique*. J Nutr, 2004. **134**(11): p. 3127-32.
- 385 20. WHO (World Health Organization), D.o.C.a.A.H.D.C., *Handbook: IMCI Integrated*
386 *Management of Childhood Illness*, UNICEF, Editor. 2004.
- 387 21. Fabiansen, C., C.W. Yameogo, A.S. Iuel-Brockdorf, B. Cichon, M.J.H. Rytter, A. Kurpad,
388 J.C. Wells, C. Ritz, P. Ashorn, S. Filteau, et al., *Effectiveness of food supplements in*
389 *increasing fat-free tissue accretion in children with moderate acute malnutrition: A*
390 *randomised 2 x 2 x 3 factorial trial in Burkina Faso*. PLoS Med, 2017. **14**(9): p.
391 e1002387.
- 392 22. Fabiansen, C., C.W. Yameogo, S. Devi, H. Friis, A. Kurpad, and J.C. Wells, *Deuterium*
393 *dilution technique for body composition assessment: resolving methodological issues*
394 *in children with moderate acute malnutrition*. Isotopes Environ Health Stud, 2017.
395 **53**(4): p. 344-355.
- 396 23. VanItallie, T.B., M.U. Yang, S.B. Heymsfield, R.C. Funk, and R.A. Boileau, *Height-*
397 *normalized indices of the body's fat-free mass and fat mass: potentially useful*
398 *indicators of nutritional status*. Am J Clin Nutr, 1990. **52**(6): p. 953-9.
- 399 24. Larnkjær, A., C. Mølgaard, and K.F. Michaelsen, *Early nutrition impact on the insulin-*
400 *like growth factor axis and later health consequences*. Curr Opin Clin Nutr Metab
401 Care, 2012. **15**(3): p. 285-92.
- 402 25. Wiley, A.S., S.M. Joshi, H.G. Lubree, D.S. Bhat, N.S. Memane, D.A. Raut, and C.S.
403 Yajnik, *IGF-I and IGFBP-3 concentrations at 2 years: associations with anthropometry*
404 *and milk consumption in an Indian cohort*. Eur J Clin Nutr, 2018. **72**(4): p. 564-571.
- 405 26. Higgins, P.B., J.R. Fernández, M.I. Goran, and B.A. Gower, *Early ethnic difference in*
406 *insulin-like growth factor-1 is associated with African genetic admixture*. Pediatr Res,
407 2005. **58**(5): p. 850-4.
- 408 27. Closa-Monasterolo, R., N. Ferré, V. Luque, M. Zaragoza-Jordana, V. Grote, M. Weber,
409 B. Koletzko, P. Socha, D. Gruszfeld, R. Janas, et al., *Sex differences in the endocrine*
410 *system in response to protein intake early in life*. Am J Clin Nutr, 2011. **94**(6 Suppl): p.
411 1920s-1927s.
- 412 28. Juul, A., K. Holm, K.W. Kastrup, S.A. Pedersen, K.F. Michaelsen, T. Scheike, S.
413 Rasmussen, J. Müller, and N.E. Skakkebaek, *Free insulin-like growth factor I serum*
414 *levels in 1430 healthy children and adults, and its diagnostic value in patients*

- 415 *suspected of growth hormone deficiency*. J Clin Endocrinol Metab, 1997. **82**(8): p.
416 2497-502.
- 417 29. Chellakooty, M., A. Juul, K.A. Boisen, I.N. Damgaard, C.M. Kai, I.M. Schmidt, J.H.
418 Petersen, N.E. Skakkebaek, and K.M. Main, *A prospective study of serum insulin-like*
419 *growth factor I (IGF-I) and IGF-binding protein-3 in 942 healthy infants: associations*
420 *with birth weight, gender, growth velocity, and breastfeeding*. J Clin Endocrinol
421 Metab, 2006. **91**(3): p. 820-6.
- 422 30. Ong, K.K., M. Langkamp, M.B. Ranke, K. Whitehead, I.A. Hughes, C.L. Acerini, and
423 D.B. Dunger, *Insulin-like growth factor I concentrations in infancy predict differential*
424 *gains in body length and adiposity: the Cambridge Baby Growth Study*. Am J Clin
425 Nutr, 2009. **90**(1): p. 156-61.
- 426 31. Savage, M.O., *Insulin-like growth factors, nutrition and growth*. World Rev Nutr Diet,
427 2013. **106**: p. 52-9.
- 428 32. Brennan, B.M., M. Gill, L. Pennells, O.B. Eden, A.G. Thomas, and P.E. Clayton, *Insulin-*
429 *like growth factor I, IGF binding protein 3, and IGFBP protease activity: relation to*
430 *anthropometric indices in solid tumours or leukaemia*. Arch Dis Child, 1999. **80**(3): p.
431 226-30.
- 432 33. Garnett, S., C.T. Cowell, D. Bradford, J. Lee, C. Tao, V. Petrauskas, R. Fay, and L.A.
433 Baur, *Effects of gender, body composition and birth size on IGF-I in 7- and 8-year-old*
434 *children*. Horm Res, 1999. **52**(5): p. 221-9.
- 435 34. Mäntyselkä, A., J. Jääskeläinen, A.M. Eloranta, J. Väistö, R. Voutilainen, K. Ong, S.
436 Brage, T.A. Lakka, and V. Lindi, *Associations of lifestyle factors with serum*
437 *dehydroepiandrosterone sulphate and insulin-like growth factor-1 concentration in*
438 *prepubertal children*. Clin Endocrinol (Oxf), 2018. **88**(2): p. 234-242.
- 439 35. Socha, P., V. Grote, D. Gruszfeld, R. Janas, H. Demmelmair, R. Closa-Monasterolo, J.E.
440 Subías, S. Scaglioni, E. Verduci, E. Dain, et al., *Milk protein intake, the metabolic-*
441 *endocrine response, and growth in infancy: data from a randomized clinical trial*. Am
442 J Clin Nutr, 2011. **94**(6 Suppl): p. 1776s-1784s.

Table 1: Characteristics of 1546 children aged 6-23 months with moderate acute malnutrition

Age, months	12.4 (\pm 4.9)
Male sex	45% (699)
Length-for-age Z-score	-1.7 (\pm 1.1)
Weight-for-age Z-score	-2.5 (\pm 0.6)
Weight-for-length Z-score	-2.2 (\pm 0.5)
Mid-upper arm circumference, mm	123 (\pm 4.0)
Illness	
<i>Ill in the last 2 weeks</i> ¹	78% (1208)
<i>Diarrhea</i> ¹	20% (304)
<i>Cough</i> ¹	29% (452)
<i>Fever (\geq37.5°C)</i> ²	17% (264)
Malaria Rapid-test positive	40% (617)
Serum concentrations	
<i>IGF-1 ng/mL</i>	12 [8.2-18.3]
<i>CRP mg/L</i>	2.3 [0.8-9.3]
<i>AGP g/L</i>	1.3 (\pm 0.66)
Body composition (n=1489)	
<i>Fat-free mass index (kg/m²)</i>	11.6 (\pm 0.9)
<i>Fat-free mass (kg)</i>	5.8 (\pm 0.9)
<i>Fat mass index (kg/m²)</i>	2.3 (\pm 0.8)
<i>Fat mass (kg)</i>	1.1 (\pm 0.4)
Breastfeeding	
<i>Still breastfed</i>	94% (1453)
<i>Previously breastfed</i>	5% (70)
<i>Never breastfed</i>	1% (21)

Values are presented as % (n), mean (\pm SD) or median [interquartile range]

Abbreviations , AGP = α_1 -acid glycoprotein, CRP = C-reactive protein, IGF-1 = Insulin-like growth factor-1

¹Based on maternal recall and physical examination at inclusion by trained study nurse

²Based on physical examination at inclusion by trained study nurse

Table 2: Anthropometry and body composition as correlates of serum IGF-1 (ng/mL) among 1546 children aged 6-23 months with moderate acute malnutrition

	N	Median [interquartile range]	Unadjusted		Age-sex adjusted	
			B (95%CI)	P-value	B (95%CI)	P-value
Admission criteria						
<i>MUAC and WLZ</i>	771	11.5 [7.9-16.8]	Ref.		Ref.	
<i>WLZ only</i>	324	11.9 [7.8-18.1]	0.8 (-0.6,2.3)	0.25	1.6 (0.2,3.1)	0.028
<i>MUAC only</i>	451	13.3 [9.4-20.6]	2.9 (1.7,4.2)	<0.001	2.2 (0.9,3.5)	0.001
Length-for-age Z-score						
≥ -2	962	12.6 [8.5-19.1]	1.2 (0.7,1.7)	<0.001	1.0 (0.5,1.5)	<0.001
< -2 and ≥ -3	426	12.0 [9.0-17.7]	Ref.		Ref.	
< -3	158	10.4 [7.2-13.1]	-1.2 (-2.5,-0.0)	0.045	-1.0 (-2.2,0.3)	0.14
			-3.5 (-5.3,-1.6)	<0.001	-2.8 (-4.7,-0.9)	0.004
Weight-for-age Z-score						
≥ -2	316	14.7 [10.1-21.9]	3.0 (2.2,3.8)	<0.001	2.6 (1.7,3.4)	<0.001
< -2 and ≥ -3	887	12.0 [8.1-17.9]	Ref.		Ref.	
< -3	343	10.8 [7.7-15.1]	-3.4 (-4.8,-2.0)	<0.001	-2.9 (-4.3,-1.5)	<0.001
			-5.4 (-7.1,-3.7)	<0.001	-4.5 (-6.2,-2.7)	<0.001
Weight-for-length Z-score						
≥ -2	455	13.3 [9.4-20.6]	3.0 (1.9,4.1)	<0.001	2.2 (1.0,3.3)	<0.001
< -2	1091	11.8 [7.9-17.2]	Ref.		Ref.	
			-3.0 (-4.2,-1.8)	<0.001	-2.1 (-3.4,-0.9)	0.001
Mid-upper arm circumference, mm						
≥ 125	324	11.9 [7.9-18.1]	0.1 (-0.0,0.3)	0.11	0.3 (0.1,0.4)	0.001
≥ 120 and < 125	873	12.5 [8.5-19.0]	Ref.		Ref.	
> 115 and < 120	349	11.4 [8.1-16.4]	0.6 (-0.8,2.0)	0.37	-0.6 (-2.0,0.9)	0.45
			-0.7 (-2.4,1.0)	0.41	-2.3 (-4.0,-0.5)	0.011
Fat-free mass index (kg/m ²)	1432		-0.2 (-0.8,0.5)	0.61	0.2 (-0.5,0.9)	0.54
Fat-free mass (kg)	1432		-0.1 (-0.8,0.5)	0.71	1.5 (0.5,2.5)	0.005
Fat mass index (kg/m ²)	1432		0.6 (-0.1,1.4)	0.097	0.4 (-0.4,1.1)	0.34
Fat mass (kg)	1432		1.4 (-0.1,2.9)	0.059	1.4 (-0.1,2.9)	0.067

Abbreviations B = Beta coefficient, IGF-1 = Insulin-like growth factor-1, MUAC = Mid-upper arm circumference, WLZ = Weight-for-length Z-score

Associations were analyzed by univariate and age- and sex adjusted linear regressions

Table 3: Breastfeeding, paraclinical and clinical markers of inflammation as correlates of serum IGF-1 (ng/mL) among 1546 children aged 6-23 months with moderate acute malnutrition

	N	Median [interquartile range]	Unadjusted		Age-sex adjusted	
			B (95%CI)	P-value	B (95%CI)	P-value
CRP mg/l						
≤2	721	12.0 [8.5-17.6]	Ref.		Ref.	
>2 and ≤5	274	13.3 [9.1-19.7]	-1.3 (-2.8,0.2)	0.10	-1.4 (-2.9,0.1)	0.065
>5 and ≤10	182	12.0 [7.6-19.6]	-1.5 (-3.3,0.3)	0.11	-1.6 (-3.4,0.1)	0.068
>10 and ≤50	277	10.5 [7.2-15.7]	-2.7 (-4.2,-1.2)	0.001	-2.6 (-4.1,-1.1)	0.001
>50	92	9.6 [7.1-12.1]	-5.4 (-7.8,-3.0)	<0.001	-5.6 (-7.9,-3.2)	<0.001
AGP g/l						
<0.8	300	15.2 [10.4-22.6]	Ref.		Ref.	
≥0.8 and ≤1.2	461	12.7 [9.0-18.8]	-2.5 (-4.1,-1.0)	0.002	-2.6 (-4.2,-1.0)	0.001
>1.2	785	10.9 [7.5-15.3]	-5.0 (-6.4,-3.5)	<0.001	-5.0 (-6.5,-3.6)	<0.001
Ill in the last 2 weeks						
No	322	14.4 [10.1-21.0]	Ref.		Ref.	
Yes	1208	11.7 [7.9-17.4]	-2.5 (-3.8,-1.1)	<0.001	-2.3 (-3.7,-1.0)	0.001
Diarrhea						
No	1242	12.7 [8.7-19.1]	Ref.		Ref.	
Yes	304	9.9 [6.9-14.4]	-2.9 (-4.3,-1.6)	<0.001	-2.6 (-4.0,-1.3)	<0.001
Cough						
No	1091	12.5 [8.7-18.9]	Ref.		Ref.	
Yes	452	11.2 [7.3-16.6]	-1.5 (-2.7,-0.3)	0.016	-1.5 (-2.8,-0.3)	0.012
Fever (≥37.5°C)						
No	1280	12.5 [8.5-19.1]	Ref.		Ref.	
Yes	264	10.5 [7.1-14.7]	-3.0 (-4.5,-1.6)	<0.001	-2.8 (-4.3,-1.4)	<0.001
Malaria (Rapid test)						
Negative	923	12.4 [8.3-19.1]	Ref.		Ref.	
Positive	617	11.8 [8.2-17.2]	-1.1 (-2.3,-0.0)	0.049	-1.1 (-2.2,0.1)	0.064
Malaria/fever						
No malaria + no fever	782	12.8 [8.5-19.5]	Ref.		Ref.	
No malaria + fever	139	10.5 [7.4-15.1]	-2.9 (-4.9,-0.9)	0.004	-2.9 (-4.9,-0.9)	0.004
Malaria + no fever	492	12.1 [8.4-18.4]	-0.9 (-2.2,0.3)	0.14	-0.9 (-2.2,0.3)	0.15
Malaria + fever	125	10.5 [6.8-14.5]	-4.0 (-6.1,-1.9)	<0.001	-3.6 (-5.7,-1.5)	0.001
Breastfeeding						
Still breastfed	1453	12.1 [8.3-18.5]	Ref.		Ref.	
Previously breastfed	70	11.2 [7.0-16.5]	-2.2 (-4.9,0.4)	0.10	-2.3 (-5.1,0.4)	0.095
Never breastfed	21	8.3 [5.1-13.3]	-4.7 (-9.5,0.03)	0.052	-5.1 (-9.8,-0.3)	0.035

Abbreviations AGP = α_1 -acid glycoprotein, B = Beta coefficient, CRP = C-reactive protein, IGF-1 = Insulin-like growth factor-1, Associations were analyzed by univariate and age- and sex adjusted linear regressions

Figure 1: Participant flow chart

Figure 2: The relationship between age and serum IGF-1 for boys and girls in 1546 children aged 6-23 months with moderate acute malnutrition. Data are presented as fractional polynomials with 95% confidence intervals.